Journal of Health Care and Prevention
Open Access

The New Blood Thinners in Atrial Fibrillation, Did They Keep Their Promise a Decade Later? And What About my Risky Older Patient?

Warning: Undefined variable $i in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156

Warning: Undefined variable $for_cr in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156
Copyright: © 2019  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

A decade after the Randomized Controlled Studies (as RCT’s) on Direct Oral Anticoagulants as DOAC’s, or as called by other names as: NOAC’s (as novel oral anticoagulants or non- vitamin K dependent oral anticoagulants) or TSOAC (as target specific oral anticoagulants), have been published what have we learned? According to the metanalyses of those RCT’s (comparison to warfarin \ VKA and not a direct comparison) all of the DOAC’s are either superior to warfarin (dabigatran 150 mg bid, apixaban) or noninferior (rivaroxaban, edoxaban, dabigatran 110 mg bid) in the reduction of stroke. An unexpected but very important finding was that all are associated with a significant reduction (around 50% RRR) in intracranial hemorrhage compared to adjusted dose of warfarin. Another important outcome was their safety, being either noninferior to warfarin with respect to major bleeds (dabigatran 150 mg bid and rivaroxaban) or result even in a significant reduction in major bleeding (dabigatran only at 110 mg bid, edoxaban, and apixaban full dose).

Keywords